logo
Plus   Neg
Share
Email

Johnson & Johnson Boosts FY20 Outlook - Quick Facts

While reporting financial results for the second quarter, healthcare company Johnson & Johnson (JNJ) on Thursday raised its earnings and sales forecast for the full year 2020.

For fiscal 2020, the company now projects adjusted earnings in a range of $7.75 to $7.95 per share and adjusted operational earnings in a range of $7.85 to $8.05 per share.

The company previously expected adjusted earnings in the range of $7.50 to $7.90 per share and adjusted operational earnings in the range of $7.65 to $8.05 per share.

Additionally, the company now projects reported sales between $79.9 billion and $81.4 billion, operational sales between $81.0 billion and $82.5 billion and adjusted operational sales change between a decline of 0.8 percent and a growth of 1.0 percent.

Earlier, the company forecast reported sales between $77.5 billion and $80.5 billion, operational sales between $79.2 billion and $82.2 billion and adjusted operational sales change between a decline of 3.0 percent and a growth of 0.5 percent.

On average, 19 analysts polled by Thomson Reuters expect the company to report earnings of $7.73 per share on a revenue decline of 3.1 percent to $79.54 billion. Analysts' estimates typically exclude special items.

"Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment," said Alex Gorsky, Chairman and Chief Executive Officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT